Stock Deep Dive · 2026-08-20
Alteogen (196170) closed at ₩339,500, up 11.86% on the day. Year-to-date return is -1.8%, sitting at 60% of its 52-week range. Earnings for the quarter were reported on 2026-08-14 (EPS ₩531 vs ₩264 consensus, +101%). Listed in Seoul — for USD-based investors, KRW moves add an FX layer on top of the stock’s local return.
|
Close
₩339,500
+11.86% · YTD -1.8%
|
Market Cap
₩23.62T
Biotechnology
|
Forward P/E
62.5x
PER 181.4x
|
52-wk Range
60%
High ₩437,692 · Low ₩194,615
|
🔍 At a Glance
Alteogen just posted a blistering quarter (+269.5% YoY revenue, 41.8% operating margin, 25.2% ROE) and the market has responded with an 11.86% single-day pop and a 61.7% one-month rally, backed by fresh licensing news and reported BlackRock buying. But at PER 181.4, forward PER 62.5, and EV/EBITDA 223.6, the stock is pricing in years of flawless execution — and with RSI at 77.7 and shares 28% above the 60-day average, a sharp pullback is a live risk regardless of fundamentals.
🏢 How It Makes Money
Alteogen is a KOSDAQ-listed biotech building long-acting “biobetter” versions of existing drugs, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars, using its NexP and NexMab platforms. Programs span human growth hormone (ALT-P1), a hemophilia therapy (ALT-Q2), targeted cancer drugs (ALT-P7, ALT-Q5), a subcutaneous trastuzumab formulation, and a Kissei-partnered Eylea biosimilar. Revenue is driven heavily by licensing and partnership deals with global pharma rather than product sales, explaining the lumpy but explosive quarterly growth.
📈 Quarterly Results — Is Business Growing?
| Quarter | Revenue | Op. Income | Net Income | Op. Margin |
|---|---|---|---|---|
| 25Q1 | ₩83.7B | ₩61.0B | ₩83.2B | 72.9% |
| 25Q2 | ₩18.6B | ₩-0.4B | ₩-33.1B | -2.3% |
| 25Q3 | ₩49.0B | ₩26.7B | ₩22.3B | 54.4% |
| 25Q4 | ₩64.5B | ₩19.6B | ₩69.2B | 30.4% |
| 26Q1 | ₩71.6B | ₩39.3B | ₩71.7B | 54.9% |
| 26Q2* | ₩68.9B | ₩34.2B | ₩28.4B | 49.6% |
* 26Q2 figures come from the company’s preliminary earnings disclosure filed with Korea’s DART on 2026-08-07. They are unaudited and will be replaced once the reviewed quarterly or half-year report is filed.
Latest-quarter revenue up +269.5% versus the same quarter a year ago.
💡 Korea Market 101
⚖️ Valuation — Cheap or Expensive?
| Metric | Value | How to read it |
|---|---|---|
| P/E (trailing) | 181.4x | Price vs last 12 months’ earnings |
| P/E (forward) | 62.5x | Price vs next 12 months’ expected earnings — growth hopes baked in |
| P/S | 115.9x | Price vs revenue — for high-growth names with thin profits |
| P/B | 53.0x | Price vs book value — below 1x means priced under liquidation value |
| EV/EBITDA | 223.6x | Enterprise value (incl. debt) vs cash generation |
Peer comparison
| Name | Mkt Cap | P/E | Fwd P/E | P/S |
|---|---|---|---|---|
| Alteogen | ₩23.62T | — | 62.5x | 115.9x |
| Celltrion | ₩44.51T | — | 25.7x | 10.0x |
| SAMSUNG BIOLOGICS | ₩72.86T | — | 32.0x | 15.1x |
💡 Korea Market 101
🎯 Street Consensus
- Price target (mean): ₩372,051
- Target high / low: ₩480,000 / ₩310,000
- Implied upside: +9.6%
- Rating: Buy (1.7/5)
- Analysts covering: 6
- Last earnings: 2026-08-14 — reported
💡 Korea Market 101
📉 Price Action — Technical Check
| Indicator | Value | How to read it |
|---|---|---|
| RSI (14d) | 77.7 | Above 70 overbought · below 30 oversold |
| vs 60-day MA | +28.1% | Above/below the medium-term trend |
| vs 200-day MA | +10.8% | Above/below the long-term trend |
| Golden/death cross | 50-day below 200-day (bearish alignment) | 50-day MA crossing above (golden) or below (death) the 200-day |
| Volume (vs 20d avg) | 1.8x | 2x+ means a spike in market attention |
💡 Korea Market 101
📰 Recent News
- Biogen Stock (BIIB) Opinions on Alteogen Partnership — Quiver Quantitative
- Why Alteogen’s Stock Price Remains Unfazed Despite ‘Triple Positive Catalysts’ — 아시아경제
- BlackRock-Fueled Alteogen Surge Drives KOSDAQ Up 7%, Triggers Buy-Side Circuit Breaker — finance.biggo.com
- [JPM 2026] Alteogen nears another massive deal: CEO — The Korea Herald
- Alteogen signs licensing deal worth up to $365 million By Investing.com — Investing.com Nigeria
- KOSDAQ Soars 7% as Top Stock Alteogen Jumps 14% — Seoul Economic Daily
How to read these headlines
The common thread is dealmaking momentum: a Biogen-linked partnership discussion, a newly signed $365 million licensing agreement, and CEO comments about another “massive deal” nearing at JPM 2026 have collectively driven institutional buying (reportedly BlackRock) and a KOSDAQ-wide surge. This matters because Alteogen’s earnings are largely licensing-driven, so each new agreement directly lifts near-term revenue and reinforces the platform’s credibility — but it also means the current price is highly sensitive to whether the rumored deal actually materializes.
Headlines are credited to their publishers — click a headline to open the original article. The commentary is written by this site and does not represent the views of any publisher.
💡 Korea Market 101
🔭 Scenarios & What to Watch
Upside case: further licensing agreements — following the reported $365 million deal and Biogen-related chatter from JPM 2026 — convert into upfront cash and milestone payments, validating the platform. Downside case: given the stretched valuation multiples and overbought technicals, any delay in a new deal, disappointing trial data, or profit-taking could trigger a sharp reversal, especially since analyst targets (average ₩372,051, low ₩310,000) sit below the current price. Watch for confirmation of deal terms, clinical updates, and the next earnings release for signs the revenue surge is sustainable rather than deal-timing driven.
💡 Korea Market 101
📚 All stock analysis · More on Alteogen · Market report for this session
Stock report · published 2026-08-20 16:00 KST
For information only — a summary of public data, not a recommendation to buy or sell any security. Source data (Yahoo Finance and others) may be delayed or contain errors. All investment decisions are your own responsibility.
Leave a Reply